2023
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea
Wang R, Shallis R, Stempel JM, Huntington SF, Zeidan AM, Gore SD, Ma X, Podoltsev NA. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. Blood Advances 2023, 7: 734-743. PMID: 35917456, PMCID: PMC9989521, DOI: 10.1182/bloodadvances.2022008259.Peer-Reviewed Original ResearchConceptsSecond malignanciesAcute myeloid leukemiaOlder patientsMyelodysplastic syndromeMyeloproliferative neoplasmsHU usersHigh riskPolycythemia veraEssential thrombocythemiaRisk of SMAML/myelodysplastic syndromeClassical Philadelphia chromosome-negative myeloproliferative neoplasmsImpact of hydroxyureaRetrospective cohort studyUse of hydroxyureaPhiladelphia chromosome-negative myeloproliferative neoplasmsClassical myeloproliferative neoplasmsCumulative incidence probabilityCohort studyCytoreductive therapyPatient characteristicsMedian ageHU useMyeloid leukemiaSecondary myelofibrosis
2020
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Advances 2020, 4: 2192-2201. PMID: 32433746, PMCID: PMC7252544, DOI: 10.1182/bloodadvances.2020001779.Peer-Reviewed Original ResearchMeSH KeywordsAgedDecitabineHumansLeukemia, Myeloid, AcuteMedicareRetrospective StudiesTreatment OutcomeUnited StatesConceptsAcute myeloid leukemiaDecitabine-treated patientsTransfusion independenceRed blood cell transfusion independenceLarge population-based studyOlder AML patientsRBC transfusion independenceEnd Results-MedicarePopulation-based studyStandard of careAgent azacitidineMedian survivalOlder patientsIntensive therapyAML patientsClinical outcomesClinical benefitMyeloid leukemiaMortality riskPatientsAzacitidineDecitabineOlder adultsOne-thirdMeaningful differencesPatterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States
Zeidan AM, Podoltsev NA, Wang X, Zhang C, Bewersdorf JP, Shallis RM, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X, Wang R. Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. Blood Advances 2020, 4: 1615-1623. PMID: 32311013, PMCID: PMC7189301, DOI: 10.1182/bloodadvances.2020001728.Peer-Reviewed Original ResearchConceptsIntensive induction chemotherapyAcute myeloid leukemiaHospital deathInduction chemotherapyAdult patientsMultivariable logistic regression modelLow hospital volumePremier Healthcare DatabasePredictors of deathHealthcare resource utilizationIntensive care unitPatterns of careStandard of careLogistic regression modelsFit patientsRemission inductionFirst hospitalizationHospital volumeInpatient deathInpatient mortalityOlder patientsSupportive careMedian ageAML patientsCare unitAge-, sex- and disease subtype–related foetal growth differentials in childhood acute myeloid leukaemia risk: A Childhood Leukemia International Consortium analysis
Karalexi MA, Dessypris N, Ma X, Spector LG, Marcotte E, Clavel J, Pombo-de-Oliveira MS, Heck JE, Roman E, Mueller BA, Hansen J, Auvinen A, Lee PC, Schüz J, Magnani C, Mora AM, Dockerty JD, Scheurer ME, Wang R, Bonaventure A, Kane E, Doody DR, Group N, Baka M, Moschovi M, Polychronopoulou S, Kourti M, Hatzipantelis E, Pelagiadis I, Dana H, Kantzanou M, Tzanoudaki M, Anastasiou T, Grenzelia M, Gavriilaki E, Sakellari I, Anagnostopoulos A, Kitra V, Paisiou A, Bouka E, Group F, Nikkilä A, Lohi O, Erdmann F, Kang A, Metayer C, Milne E, Petridou E. Age-, sex- and disease subtype–related foetal growth differentials in childhood acute myeloid leukaemia risk: A Childhood Leukemia International Consortium analysis. European Journal Of Cancer 2020, 130: 1-11. PMID: 32163883, DOI: 10.1016/j.ejca.2020.01.018.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsCase-Control StudiesChildChild, PreschoolFemaleFetal DevelopmentHumansInfantInfant, NewbornLeukemia, Myeloid, AcuteMaleSex FactorsConceptsAcute myeloid leukemiaChildhood Leukemia International ConsortiumGestational ageFoetal growthInfant boyAcute myeloid leukemia riskMyeloid leukemia riskNewborn Growth ConsortiumRare childhood cancerBirth lengthGrowth markersChildhood cancerAML subtypesAML casesMyeloid leukemiaLeukemia riskNull associationDisease subtypesInternational FetalAgeMore studiesConsortium analysisLeukemiaSexBoys
2019
Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population‐level analysis
Zeidan AM, Podoltsev NA, Wang X, Bewersdorf JP, Shallis RM, Huntington SF, Gore SD, Davidoff AJ, Ma X, Wang R. Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population‐level analysis. Cancer 2019, 125: 4241-4251. PMID: 31483484, PMCID: PMC7733320, DOI: 10.1002/cncr.32439.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleHumansLeukemia, Myeloid, AcuteMaleRetrospective StudiesSEER ProgramUnited StatesConceptsAcute myeloid leukemiaTime of diagnosisOlder patientsActive treatmentMyeloid leukemiaMultivariable logistic regression modelMedian overall survivalPercentage of patientsLow-intensity therapyMajority of patientsNovel therapeutic optionsQuality of careLogistic regression modelsIntensity therapyTherapy receiptOverall survivalWorse survivalClinical factorsInferior survivalEntire cohortTherapeutic optionsPatient populationRetrospective analysisHigher oddsProvider characteristicsHealthcare expenses for treatment of acute myeloid leukemia
Bewersdorf JP, Shallis R, Wang R, Huntington S, Perreault S, Ma X, Zeidan AM. Healthcare expenses for treatment of acute myeloid leukemia. Expert Review Of Hematology 2019, 12: 641-650. PMID: 31159602, DOI: 10.1080/17474086.2019.1627869.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntineoplastic AgentsCost-Benefit AnalysisHealth Care CostsHematopoietic Stem Cell TransplantationHospitalizationHumansLeukemia, Myeloid, AcuteConceptsHematopoietic stem cell transplantInsurance statusHealthcare costsTreatment approachesAllogeneic hematopoietic stem cell transplantAcute myeloid leukemia (AML) treatmentStem cell transplantTreatment costsDirect healthcare costsInpatient treatment costsPatient insurance statusPersonalized treatment approachesAcute myeloid leukemiaMyeloid leukemia treatmentInfluence health policyIntensive chemotherapyOral therapyCell transplantMain cost driversMyeloid leukemiaNovel agentsMedical outcomesLeukemia treatmentHealthcare resourcesAMLEpidemiology of acute myeloid leukemia: Recent progress and enduring challenges
Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Reviews 2019, 36: 70-87. PMID: 31101526, DOI: 10.1016/j.blre.2019.04.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaPatient outcomesMyeloid leukemiaAllogeneic stem cell transplantationEtiology of AMLMinority of patientsStem cell transplantationAge-adjusted incidenceMost older individualsMyeloid progenitor cellsIntensive chemotherapyActive therapyClear etiologyOlder patientsRefractory diseaseSupportive careCurative therapyMedian agePoor prognosisShorter survivalCell transplantationDisease characteristicsEnvironmental DNA-damaging agentsMalignant disordersTherapeutic advancesParental age and the risk of childhood acute myeloid leukemia: results from the Childhood Leukemia International Consortium
Panagopoulou P, Skalkidou A, Marcotte E, Erdmann F, Ma X, Heck JE, Auvinen A, Mueller BA, Spector LG, Roman E, Metayer C, Magnani C, Pombo-de-Oliveira MS, Scheurer ME, Mora AM, Dockerty JD, Hansen J, Kang AY, Wang R, Doody DR, Kane E, Schüz J, Christodoulakis C, Ntzani E, Petridou ET, group F, group N. Parental age and the risk of childhood acute myeloid leukemia: results from the Childhood Leukemia International Consortium. Cancer Epidemiology 2019, 59: 158-165. PMID: 30776582, PMCID: PMC7098424, DOI: 10.1016/j.canep.2019.01.022.Peer-Reviewed Original ResearchConceptsChildhood Leukemia International ConsortiumAcute myeloid leukemiaAML riskOdds ratioMyeloid leukemiaParental ageChildhood acute myeloid leukemiaPaternal age groupsInfants of mothersConfidence intervalsAdvanced maternal ageMultiple logistic regressionPooled-effect estimatesInfant acute myeloid leukemiaMaternal smokingMultiple gestationsMaternal ageChildhood cancerAML casesAge groupsLogistic regressionStudy designAge incrementsOlder childrenAge
2016
Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population‐Based Study
Wang R, Zeidan AM, Yu JB, Soulos PR, Davidoff AJ, Gore SD, Huntington SF, Gross CP, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population‐Based Study. The Prostate 2016, 77: 437-445. PMID: 27868212, PMCID: PMC5785924, DOI: 10.1002/pros.23281.Peer-Reviewed Original ResearchConceptsMDS/acute myeloid leukemiaAcute myeloid leukemiaProstate cancer patientsElderly prostate cancer patientsImpact of radiotherapyCancer patientsMyelodysplastic syndromeNational Cancer Institute's SurveillanceSubsequent myelodysplastic syndromeEnd Results-MedicareRetrospective cohort studyRole of radiotherapyInformed treatment decisionsUnderwent radiotherapyIMRT groupCohort studyPatient characteristicsMedian timeMyeloid leukemiaProstate cancerTreatment decisionsPatientsRadiotherapyMyeloid malignanciesSurgeryConnect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study
Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X, Maciejewski J, Pollyea DA, Savona MR, Scott B, Sekeres MA, Thompson MA, Swern AS, Nifenecker M, Sugrue MM, Erba H. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. BMC Cancer 2016, 16: 652. PMID: 27538433, PMCID: PMC4991094, DOI: 10.1186/s12885-016-2710-6.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overFemaleHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMyelodysplastic SyndromesProspective StudiesQuality of LifeRegistriesSample SizeUnited StatesConceptsAcute myeloid leukemiaObservational cohort studyDisease RegistryCohort studyClinical outcomesPatient-reported health-related qualityProspective observational cohort studyBaseline patient characteristicsHigh-risk MDSHealth-related qualityNon-interventional studyPatient-reported outcomesLower-risk MDSHealth economic outcomesMinimal diagnostic criteriaRoutine clinical settingNatural history studiesBackgroundMyelodysplastic syndromesPersistent cytopeniasOlder patientsPatient characteristicsTreatment patternsAlternate diagnosisCentral reviewMyelodysplastic syndrome
2009
Diet, Lifestyle, and Acute Myeloid Leukemia in the NIH–AARP Cohort
Ma X, Park Y, Mayne ST, Wang R, Sinha R, Hollenbeck AR, Schatzkin A, Cross AJ. Diet, Lifestyle, and Acute Myeloid Leukemia in the NIH–AARP Cohort. American Journal Of Epidemiology 2009, 171: 312-322. PMID: 20042434, PMCID: PMC2842202, DOI: 10.1093/aje/kwp371.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaPack/dayMyeloid leukemiaHazard ratioMeat intakeNIH-AARP DietLarge prospective studiesMultivariate Cox modelHigh meat intakeMeat cooking methodsNIH-AARP cohortCurrent smokersFormer smokersIncident casesProspective studyUS cohortVegetable intakeDoneness levelRisk factorsHigh riskCox modelHealth StudyLeukemiaSmokersConfidence intervals
2005
Maternal Pregnancy Loss, Birth Characteristics, and Childhood Leukemia (United States)
Ma X, Metayer C, Does MB, Buffler PA. Maternal Pregnancy Loss, Birth Characteristics, and Childhood Leukemia (United States). Cancer Causes & Control 2005, 16: 1075-1083. PMID: 16184473, DOI: 10.1007/s10552-005-0356-9.Peer-Reviewed Original ResearchMeSH KeywordsAbortion, SpontaneousAdolescentBirth CertificatesBirth IntervalsBirth OrderBirth WeightCaliforniaCase-Control StudiesChildChild, PreschoolFemaleHumansInfantInfant, NewbornLeukemia, Myeloid, AcuteMalePrecursor Cell Lymphoblastic Leukemia-LymphomaPregnancyPregnancy, High-RiskRisk AssessmentRisk FactorsConceptsBirth characteristicsPregnancy lossChildhood leukemiaOdds ratioNorthern California Childhood Leukemia StudyHistory of miscarriageConfidence intervalsRisk of AMLConditional logistic regressionDetailed reproductive historyCalifornia Childhood Leukemia StudyChildhood Leukemia StudyChildhood AMLIncident casesBirth weightMaternal historyIndex childReproductive historyBirth recordsLogistic regressionRecall biasBirth certificatesLeukemia StudyAMLLeukemiaMolecular biomarkers for the study of childhood leukemia
Smith MT, McHale CM, Wiemels JL, Zhang L, Wiencke JK, Zheng S, Gunn L, Skibola CF, Ma X, Buffler PA. Molecular biomarkers for the study of childhood leukemia. Toxicology And Applied Pharmacology 2005, 206: 237-245. PMID: 15967214, DOI: 10.1016/j.taap.2004.11.026.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAcute lymphocytic leukemiaChildhood leukemiaLeukemia riskChildhood acute lymphocytic leukemiaC609T polymorphismLow folate intakeNeonatal blood spotsYears of lifeMethylenetetrahydrofolate reductase (MTHFR) geneDifferent cytogenetic subgroupsPerinatal exposureFolate intakeMyeloid leukemiaLymphocytic leukemiaT polymorphismUseful biomarkerInfectious agentsAberrant gene methylationLeukemiaCytogenetic subgroupsBlood spotsMolecular biomarkersIndoor pesticidesGene methylation